Spectrum Pharmaceuticals

24 articles with Spectrum Pharmaceuticals

• Spectrum Pharmaceuticals Presents Poziotinib Data in Patients with Brain Metastases from the ZENITH20 Clinical Trial at 2021 ASCO Annual Meeting

  6/4/2021

  Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented an e-poster on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations

• Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated

  6/1/2021

  Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced that the U.S. Food and Drug Administration is “on site” for the ROLONTIS® manufacturing facility inspection.

• Spectrum Pharmaceuticals to Present Data for Poziotinib in Patients with Brain Metastases at the Upcoming 2021 ASCO Annual Meeting

  5/28/2021

  Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations.

• Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences in June

  5/27/2021

  Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conferences: Jefferies Virtual Healthcare Conference 2021 . A fireside chat presentation is scheduled for Thursday, June 3, 2021, at 9:30 a.m.

• Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update

  5/13/2021

  Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2021 and provided a corporate update

• Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update

  5/6/2021

  Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2021 financial results and provide a corporate update on Thursday, May 13, 2021 at 4:30 p.m. Eastern/1:30 p.m. Pacific.

• Spectrum Pharmaceuticals Presents Additional Twice Daily Dosing Data for Poziotinib at the AACR Virtual Meeting 2021

  4/10/2021

  Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, presented a data update on the safety and tolerability of twice daily administered poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations.

• Spectrum Pharmaceuticals Presentations at the Upcoming AACR Virtual Meeting 2021 to Include Updated Poziotinib Twice Daily Dosing Data

  4/5/2021

  Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced a poster presentation on safety and tolerability of twice daily administered poziotinib in patients with EGFR or HER2 exon 20 mutations.

• Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update

  3/30/2021

  Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2020.

• Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

  3/26/2021

  Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2020 financial results and provide a corporate update on Tuesday, March 30, 2021 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Tuesday, March 30, 20201 @ 4:30 p.m. Eastern/1:

• Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection

  3/16/2021

  Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced that the U.S. Food and Drug Administration has scheduled the pre-approval inspection at the ROLONTIS® manufacturing site in May 2021.

• FDA Grants Fast Track Designation to Spectrum Pharmaceuticals’ Poziotinib

  3/11/2021

  Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for poziotinib for the treatment of non-small cell lung cancer (NSCLC)

• Spectrum Pharmaceuticals Presents Twice Daily Dosing Data for Poziotinib at the ESMO TAT Virtual Congress 2021

  3/2/2021

  Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented results from Cohort 3 and initial twice daily (BID) dosing safety and efficacy data for poziotinib from Cohort 5 of the ZENITH20 clinical trial. These preliminary data demonstrate improved tolerability with BID dosing, reduced dose interruption compared to once daily (QD) dosing

• Spectrum Pharmaceuticals Announces Poster Presentation at Upcoming Miami Breast Cancer Conference

  2/26/2021

  Spectrum Pharmaceuticals Announces Poster Presentation at Upcoming Miami Breast Cancer Conference

• Spectrum Pharmaceuticals Announces Two Presentations at Upcoming ESMO TAT Virtual Congress 2021

  2/23/2021

  Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021.

• Spectrum Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2021 Oncology Day

  2/4/2021

  Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day. The fireside chat is scheduled for Thursday, February 11, 2021, at 4 p.m. EST.

• Spectrum Pharmaceuticals Announces Two Oral Presentations at Upcoming IASLC 2020 World Conference on Lung Cancer

  1/22/2021

  Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. In addition, Spectrum also announced an oral presentation on the structural classification of atypical EGFR mutations and their patterns of drug sensitivity.

• Spectrum Pharmaceuticals to Participate in Three Upcoming Investor Conferences in January 2021

  1/5/2021

  Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced that management will provide an overview of the company's business strategy and development-stage programs at three upcoming virtual investor conferences:

• Spectrum Provides Poziotinib Update after Successful Pre-NDA Meeting with the FDA

  12/22/2020

  FDA agrees to the submission of an NDA for poziotinib for non-small cell lung cancer (NSCLC) in previously treated patients with HER2 exon 20 insertion mutations, NDA submission planned for 2021 Cohort 3 of the ZENITH20 clinical trial, which enrolled first-line NSCLC patients with EGFR exon 20 insertion mutations at 16mg once daily, did not meet its primary endpoint

• Unicycive Therapeutics Acquires Renazorb (Lanthanum Dioxycarbonate) from Spectrum Pharmaceuticals for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease

  12/14/2020

  Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced it has entered a licensing agreement with Spectrum Pharmaceuticals for Renazorb (lanthanum dioxycarbonate), a late-stage asset for the treatment of hyperphosphatemia in patients with chronic kidn